Xgeva®120mg Solution for Injection (denosumab): Updated recommendations to minimise the risk of severe symptomatic hypocalcaemia (SSH) and osteonecrosis of the jaw (ONJ)

User Rating: 0 / 5

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

Date: 23 March 2015

Description:

The NPCB has approved a Direct Healthcare Professional Communication (DHPC) on new recommendations to reduce the risk of SSH and ONJ associated with Xgeva®. Calcium levels should be monitored prior to starting the drug and through treatment. Patients are recommended to undergo a dental examination with appropriate preventive dentistry before starting therapy, and practice good oral hygiene. GlaxoSmithKline Pharmaceuticals (M) Sdn. Bhd.is updating the prescribing information Xgeva® to reflect this new safety information. Further information can be obtained from the DHPC.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA